Expression of CXC chemokine receptor‑4 and forkhead box 3 in neuroblastoma cells and response to chemotherapy

Sun,Jing; Feng,Chen; Liao,Weiwei; Zhang,Hao; Tang,Suoqin

doi:10.3892/ol.2014.2028

Expression of CXC chemokine receptor‑4 and forkhead box 3 in neuroblastoma cells and response to chemotherapy

Authors:
- Jing Sun
- Chen Feng
- Weiwei Liao
- Hao Zhang
- Suoqin Tang
View Affiliations

Affiliations: Department of Pediatrics, Chinese PLA General Hospital 304, Beijing 100037, P.R. China, Department of Pediatrics, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: April 3, 2014 https://doi.org/10.3892/ol.2014.2028
Pages: 2083-2088

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Current evidence indicates that the abnormal expression of chemokines or their receptors, such as CXC chemokine receptor‑4 (CXCR4), is positively correlated with the development, progression and metastasis of tumor cells. However, the role of CXCR4 in neuroblastoma and its response to chemotherapy remain largely unclear. In addition, forkhead box 3 (Foxp3), a transcription factor associated with T cell tolerance, is expressed in tumor cells and plays a role in the immune evasion of cancers. The present study aimed to examine the expression of CXCR4 and Foxp3 in the LAN‑5 and SK‑N‑SH neuroblastoma cell lines. The effects of chemotherapy drugs, cyclophosphamide (CTX) and pirarubicin (THP), on the expression of these two genes were also investigated. Our findings indicated that CXCR4 and Foxp3 were highly expressed in LAN‑5 and SK‑N‑SH cells. Following treatment with CTX and THP, the protein expression of CXCR4 in LAN‑5 and SK‑N‑SH cells was significantly decreased (P<0.05). The expression of Foxp3 in LAN‑5 cells was also significantly downregulated by CTX and THP treatment (P<0.05). Therefore, the high expression of CXCR4 and Foxp3 in LAN‑5 and SK‑N‑SH cells and their subsequent downregulation following administration of the chemotherapy agents suggests that the chemokine receptors, CXCR4 and Foxp3, may be involved in the metastasis and tumor evasion of neuroblastoma. Further studies should investigate the expression of CXCR4 and Foxp3 in patient samples.

View Figures

View References

1	Guerreiro R, Santos-Costa Q and Azevedo-Pereira JM: The chemokines and their receptors: characteristics and physiological functions. Acta Med Port. 24(Suppl 4): 967–976. 2011.(In Portugese).
2	Ito H: Chemokines in mesenchymal stem cell therapy for bone repair: a novel concept of recruiting mesenchymal stem cells and the possible cell sources. Mod Rheumatol. 21:113–121. 2011.PubMed/NCBI
3	Salazar N, Castellan M, Shirodkar SS and Lokeshwar BL: Chemokines and chemokine receptors as promoters of prostate cancer growth and progression. Crit Rev Eukaryot Gene Expr. 23:77–91. 2013. View Article : Google Scholar : PubMed/NCBI
4	Singh R, Lillard JW Jr and Singh S: Chemokines: key players in cancer progression and metastasis. Front Biosci (Schol Ed). 3:1569–1582. 2011. View Article : Google Scholar : PubMed/NCBI
5	Felix AS, Edwards R, Bowser R and Linkov F: Chemokines and cancer progression: a qualitative review on the role of stromal cell-derived factor 1-alpha and CXCR4 in endometrial cancer. Cancer Microenviron. 3:49–56. 2010. View Article : Google Scholar : PubMed/NCBI
6	Wald O, Shapira OM and Izhar U: CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics. 3:26–33. 2013. View Article : Google Scholar : PubMed/NCBI
7	Mo W, Chen J, Patel A, et al: CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 152:1077–1090. 2013. View Article : Google Scholar : PubMed/NCBI
8	Li B, Saouaf SJ, Samanta A, Shen Y, Hancock WW and Greene MI: Biochemistry and therapeutic implications of mechanisms involved in FOXP3 activity in immune suppression. Curr Opin Immunol. 19:583–588. 2007. View Article : Google Scholar : PubMed/NCBI
9	Zeestraten EC, Van Hoesel AQ, Speetjens FM, et al: FoxP3- and CD8-positive infiltrating immune cells together determine clinical outcome in colorectal cancer. Cancer Microenviron. 6:31–39. 2013. View Article : Google Scholar : PubMed/NCBI
10	Milne K, Köbel M, Kalloger SE, et al: Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 4:e64122009. View Article : Google Scholar : PubMed/NCBI
11	Mercer F and Unutmaz D: The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer. Adv Exp Med Biol. 665:47–59. 2009. View Article : Google Scholar : PubMed/NCBI
12	Garaventa A, Parodi S, De Bernardi B, et al: Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 45:2835–2842. 2009. View Article : Google Scholar : PubMed/NCBI
13	Cabioglu N, Sahin A, Doucet M, et al: Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis. 22:39–46. 2005. View Article : Google Scholar : PubMed/NCBI
14	Porvasnik S, Sakamoto N, Kusmartsev S, et al: Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate. 69:1460–1469. 2009. View Article : Google Scholar : PubMed/NCBI
15	Tao H, Mimura Y, Aoe K, et al: Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 75:95–101. 2012. View Article : Google Scholar : PubMed/NCBI
16	Droeser R, Zlobec I, Kilic E, et al: Differential pattern and prognostic significance of CD4⁺, FOXP3⁺ and IL-17⁺ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer. 12:1342012.PubMed/NCBI
17	Li YG, He JH, Yu L, et al: microRNA-202 suppresses MYCN expression under the control of E2F1 in the neuroblastoma cell line LAN-5. Mol Med Rep. 9:541–546. 2014.PubMed/NCBI
18	Chen YX, Chen XW, Li CG, Yue LJ, Mai HR and Wen FQ: Effect of tumor gangliosides on tyrosine phosphorylation of p125FAK in platelet adhesion to collagen. Oncol Rep. 29:343–348. 2013.PubMed/NCBI
19	Li K, Dong K, Gao J, Yao W, Xiao X and Zheng S: Neuroblastoma management in Chinese children. J Invest Surg. 25:86–92. 2012. View Article : Google Scholar : PubMed/NCBI
20	Navalkele P, O’Dorisio MS, O’Dorisio TM, Zamba GK and Lynch CF: Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975–2006. Pediatr Blood Cancer. 56:50–57. 2011.PubMed/NCBI
21	Gains J, Mandeville H, Cork N, Brock P and Gaze M: Ten challenges in the management of neuroblastoma. Future Oncol. 8:839–858. 2012. View Article : Google Scholar : PubMed/NCBI
22	Øra I and Eggert A: Progress in treatment and risk stratification of neuroblastoma: impact on future clinical and basic research. Semin Cancer Biol. 21:217–228. 2011.PubMed/NCBI
23	Sharp SE, Gelfand MJ and Shulkin BL: Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med. 41:345–353. 2011. View Article : Google Scholar
24	Hesselgesser J, Liang M, Hoxie J, et al: Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity. J Immunol. 160:877–883. 1998.PubMed/NCBI
25	Zeelenberg IS, Ruuls-Van Stalle L and Roos E: The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 63:3833–3839. 2003.PubMed/NCBI
26	Hiller DJ, Meschonat C, Kim R, Li BD and Chu QD: Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer. Surgery. 150:459–465. 2011. View Article : Google Scholar : PubMed/NCBI
27	Jung SJ, Kim CI, Park CH, et al: Correlation between chemokine receptor CXCR4 expression and prognostic factors in patients with prostate cancer. Korean J Urol. 52:607–611. 2011. View Article : Google Scholar : PubMed/NCBI
28	Tarnowski M, Grymula K, Reca R, et al: Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. Mol Cancer Res. 8:1–14. 2010. View Article : Google Scholar : PubMed/NCBI
29	Li H, Zhao H, Yu J, et al: Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin. Cancer Immunol Immunother. 60:1587–1596. 2011. View Article : Google Scholar : PubMed/NCBI
30	Ikemoto T, Yamaguchi T, Morine Y, et al: Clinical roles of increased populations of Foxp3⁺CD4⁺ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas. 33:386–390. 2006.PubMed/NCBI
31	Lucas S, van Baren N, de Smet C and Coulie PG: Demethylation of the FOXP3 gene in human melanoma cells precludes the use of this epigenetic mark for quantification of Tregs in unseparated melanoma samples. Int J Cancer. 130:1960–1966. 2012. View Article : Google Scholar : PubMed/NCBI
32	Zuo T, Liu R, Zhang H, et al: FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest. 117:3765–3773. 2007.PubMed/NCBI
33	Fu HY, Li C, Yang W, et al: FOXP3 and TLR4 protein expression are correlated in non-small cell lung cancer: implications for tumor progression and escape. Acta Histochem. 115:151–157. 2013. View Article : Google Scholar : PubMed/NCBI
34	Merlo A, Tagliabue E, Mènard S and Balsari A: Matured human monocyte-derived dendritic cells (MoDCs) induce expansion of CD4⁺CD25⁺FOXP3⁺ T cells lacking regulatory properties. Immunol Lett. 117:106–113. 2008. View Article : Google Scholar : PubMed/NCBI